<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431142</url>
  </required_header>
  <id_info>
    <org_study_id>CLOPIL08732</org_study_id>
    <nct_id>NCT03431142</nct_id>
  </id_info>
  <brief_title>Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial</brief_title>
  <acronym>OPT-BIRISK</acronym>
  <official_title>Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guidelines recommend that patients with ACS undergoing stent implantation might be&#xD;
      offered extended DAPT treatment for up to 30 months if necessary.&#xD;
&#xD;
      Therefore, we designed a prospective, multicenter, randomized, placebo-controlled trial among&#xD;
      ACS patients with high-risk on ischemic and bleeding who received a new generation of DES and&#xD;
      received 9 to 12 months of DAPT, and evaluated whether clopidogrel monotherapy reduce the&#xD;
      risk of bleeding compared with clopidogrel plus ASA in the following 9 months and achieved&#xD;
      non-inferior outcomes in preventing ischemic risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines recommend that patients with ACS undergoing stent implantation might be&#xD;
      offered extended DAPT treatment for up to 30 months if necessary. For patients with high risk&#xD;
      of both ischemic and hemorrhage, despite prolonged use of DAPT may bring antithrombotic&#xD;
      benefit, it may also increase the risk of bleeding. There is an urgent need for specific&#xD;
      guiding on intensive antiplatelet therapy in this population of patients to reduce the risk&#xD;
      of ischemia and to avoid the risk of bleeding.&#xD;
&#xD;
      Previous studies have shown that, after 12 months of DAPT treatment, continuation of&#xD;
      clopidogrel monotherapy may further reduce the risk of ischemia and bleeding compared with&#xD;
      aspirin. Therefore, we designed a prospective, multicenter, randomized, placebo-controlled&#xD;
      trial among ACS patients with high-risk on ischemic and bleeding who received a new&#xD;
      generation of DES and received 9 to 12 months of DAPT, and evaluated whether clopidogrel&#xD;
      monotherapy reduce the risk of bleeding compared with clopidogrel plus ASA in the following 9&#xD;
      months and achieved non-inferior outcomes in preventing ischemic risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical relevant bleeding events</measure>
    <time_frame>During 9-month follow up</time_frame>
    <description>defined as BARC type 2-5 bleeding events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All bleeding events</measure>
    <time_frame>During 9-month follow up</time_frame>
    <description>defined all BARC type 1-5 bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events(MACCE)</measure>
    <time_frame>During 9-month follow up</time_frame>
    <description>defined as a composite endpoints of all-cause death, myofarction, stroke and clinically indicated revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7700</enrollment>
  <condition>Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Clopidogrel monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel plus aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)</description>
    <arm_group_label>Clopidogrel monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel+aspirin</intervention_name>
    <description>Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)</description>
    <arm_group_label>Clopidogrel plus aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ACS patients undergoing PCI (New-Generation DES) and finishing 9-12 months of DAPT&#xD;
&#xD;
          -  18 ~ 85 years old adult patients&#xD;
&#xD;
          -  Patients under the age of 65 must meet at least one of the following clinical criteria&#xD;
             of high bleeding risk and at least one of the following clinical criteria of high&#xD;
             ischemic risk; Patients aged 65-75 must meet one of the following clinical criteria of&#xD;
             either high bleeding risk or high ischemic risk.&#xD;
&#xD;
        Clinical criteria of high bleeding risk:&#xD;
&#xD;
          -  ≥75 years old&#xD;
&#xD;
          -  female&#xD;
&#xD;
          -  Iron deficiency anemia&#xD;
&#xD;
          -  history of stroke (hemorrhagic or ischemic)&#xD;
&#xD;
          -  ongoing medical treatment of diabetes (oral hypoglycemic agents or subcutaneous&#xD;
             insulin)&#xD;
&#xD;
          -  Chronic kidney disease (eGFR &lt;60mL/min or creatinine clearance&lt;60mL/min)&#xD;
&#xD;
        Clinical criteria of high ischemic risk:&#xD;
&#xD;
          -  ≥75 years old&#xD;
&#xD;
          -  Multiple coronary lesions&#xD;
&#xD;
          -  target lesions required for stent of total length&gt; 30mm&#xD;
&#xD;
          -  Thrombotic target lesions&#xD;
&#xD;
          -  Bifurcation lesions are Medina 0, 1, 1 or 1, 1, and 1, with stents implanted in both&#xD;
             main branch and side branch&#xD;
&#xD;
          -  Left main coronary artery (≥50%) or proximal LAD (≥70%) lesions&#xD;
&#xD;
          -  Calcified plaques requiring endovascular excision&#xD;
&#xD;
          -  acute coronary syndrome with troponin positive&#xD;
&#xD;
          -  Previous myocardial infarction, ischemic stroke, diagnosed peripheral arterial disease&#xD;
             (PAD), or revascularization due to coronary artery disease (CAD) / PAD&#xD;
&#xD;
          -  recurrent myocardial infarction, revascularization, stent thrombosis, stroke in the&#xD;
             last 9 months&#xD;
&#xD;
          -  ongoing medical treatment of diabetes (oral hypoglycemic agents or subcutaneous&#xD;
             insulin)&#xD;
&#xD;
          -  Chronic kidney disease (eGFR&lt;60 mL/min or creatinine clearance &lt;60 mL/min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Discontinuation or termination of DAPT treatment during the past 6 months due to&#xD;
             adverse events (bleeding or ischemia) or other conditions&#xD;
&#xD;
          -  Surgery plan within 90 days&#xD;
&#xD;
          -  Coronary Revascularization (Surgical or Intervention) Program within 90 days&#xD;
&#xD;
          -  Dialysis-dependent renal failure&#xD;
&#xD;
          -  Moderate or severe hepatic insufficiency (2 times the upper limit of normal for ALT or&#xD;
             AST)&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Women with childbearing potential&#xD;
&#xD;
          -  Platelet count &lt;100000/mm3&#xD;
&#xD;
          -  Subjects undergoing warfarin or similar anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Li, MD</last_name>
      <phone>+86-24-28897309</phone>
      <email>doctorliyi@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J. 2020 Oct;228:1-7. doi: 10.1016/j.ahj.2020.07.005. Epub 2020 Jul 9.</citation>
    <PMID>32739652</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

